Mark A. Schroeder

12.2k citations

213 papers · 7.0k indexed · 1 hit paper · h-index 50

Molecular Biology top 2%
Genetics top 0.2%
Oncology top 1%
Hematology top 0.5%
Immunology top 2%

Co-authors: Jann N. Sarkaria Brett L. Carlson John F. DiPersio Mark S. Wrighton C. David James Rolf D. Hubmayr Nicholas E. Vlahakis Evanthia Galanis
Topics: Hematopoietic Stem Cell Transplantation (50 papers)Glioma Diagnosis and Treatment (36 papers)Acute Myeloid Leukemia Research (34 papers)
Cited by: Genetics Hematology Oncology
Journals: Journal of the American Chemical Society Journal of Clinical Oncology Genes & Development
Partner nations: United States Canada Australia

In The Last Decade

Mark A. Schroeder

200 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression

2013 489 citations Mark A. Schroeder, C. David James et al. profile →

Peers

Countries citing papers authored by Mark A. Schroeder

Since Specialization

Citations

This map shows the geographic impact of Mark A. Schroeder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Schroeder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Schroeder more than expected).

Fields of papers citing papers by Mark A. Schroeder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Schroeder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Schroeder. The network helps show where Mark A. Schroeder may publish in the future.

Co-authorship network of co-authors of Mark A. Schroeder

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Schroeder. A scholar is included among the top collaborators of Mark A. Schroeder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Schroeder. Mark A. Schroeder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II Study of Peri- and Post-Transplant Ruxolitinib for Patients With Myelofibrosis Receiving Allogeneic Hematopoietic Cell Transplantation 2025 ·Gabriela Hobbs,Haesook T. Kim,(unknown),Mark A. Schroeder,Roni Tamari,Sarah Wall,(unknown),Areej El‐Jawahri,Matthew J. Frigault,Steven L. McAfee,Richard Newcomb,Paul V. O’Donnell,Thomas R. Spitzer,Jonas S. Jutzi,Yi‐Bin Chen,Zachariah DeFilipp	1
2	Patient Recorded Outcomes from a Randomized, Controlled Phase 2 Trial of E-Selectin Inhibition with Uproleselan Vs Placebo to Reduce GI Toxicity during Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation for Multiple Myeloma 2023 ·Blood ·(unknown),Zachary Crees,Michael Slade,Mark A. Schroeder,Ravi Vij,Geoffrey L. Uy,Keith Stockerl‐Goldstein	1
3	Prolonged Post-Transplant Ruxolitinib Therapy is Associated with Protection from Severe Gvhd after Allogeneic HCT 2022 ·Transplantation and Cellular Therapy ·Zachariah DeFilipp,Haesook T. Kim,Laura Knight,(unknown),Michael Byrne,Mark A. Schroeder,Roni Tamari,Sarah Wall,Sumithira Vasu,Sameem Abedin,Areej El‐Jawahri,Steven L. McAfee,Yi‐Bin Chen,Gabriela Hobbs	2
4	A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation 2022 ·Transplantation and Cellular Therapy ·Ramzi Abboud,Feng Gao,Michael P. Rettig,(unknown),Leah Gehrs,Nicholas A. Wallace,Camille N. Abboud,Peter Westervelt,Geoffrey L. Uy,Amanda F. Cashen,Matthew Christopher,Armin Ghobadi,Meagan A. Jacoby,Iskra Pusic,Keith Stockerl-Goldstein,John F. DiPersio,Mark A. Schroeder	1
5	Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program 2022 ·Bone Marrow Transplantation ·Mark A. Schroeder,Parameswaran Hari,(unknown),Dilan Paranagama,Valkal Bhatt,John F. DiPersio	7
6	In Vivo Efficacy of Tesevatinib in EGFR -Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling 2021 ·Molecular Cancer Therapeutics ·Sani H. Kizilbash,Shiv K. Gupta,Karen E. Parrish,Janice K. Laramy,Minjee Kim,Gautham Gampa,Brett L. Carlson,Katrina K. Bakken,Ann C. Mladek,Mark A. Schroeder,Paul A. Decker,William F. Elmquist,Jann N. Sarkaria	10
7	A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease 2020 ·Blood Advances ·Mark A. Schroeder,H. Jean Khoury,Madan Jagasia,Haris Ali,Gary J. Schiller,Karl Staser,Jaebok Choi,Leah Gehrs,Michael Arbushites,Ying Yan,Peter Langmuir,(unknown),Michael A. Pratta,Miguel‐Angel Perales,Yi‐Bin Chen,Gabrielle Meyers,John F. DiPersio	72
8	A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma 2019 ·Clinical Cancer Research ·Joseph M. Tuscano,Emanual Maverakis,Susan Groshen,Denice Tsao‐Wei,Guillaume Luxardi,Alexander A. Merleev,Anne Beaven,John F. DiPersio,Leslie Popplewell,Robert Chen,Mark Kirschbaum,Mark A. Schroeder,Edward M. Newman	34
9	A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure 2018 ·Clinical Cancer Research ·Amer M. Zeidan,Hanna A. Knaus,Tara M. Robinson,Andrea Towlerton,Edus H. Warren,Joshua F. Zeidner,Amanda L. Blackford,Amy S. Duffield,David A. Rizzieri,Mark G. Frattini,Yair Levy,Mark A. Schroeder,Anna Ferguson,(unknown),Amy E. DeZern,Ivana Gojo,Steven D. Gore,Howard Streicher,Leo Luznik,B. Douglas Smith	74
10	Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS 2018 ·Clinical Cancer Research ·Michael R. Savona,Daniel A. Pollyea,Wendy Stock,Vivian G. Oehler,Mark A. Schroeder,Jeffrey E. Lancet,James McCloskey,Hagop M. Kantarjian,Weidong Wendy,M. Naveed Shaik,Alexander Laird,Mirjana Zeremski,Ashleigh O’Connell,Geoffrey Chan,Jörge E. Cortes	86
11	Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma 2017 ·Molecular Cancer Therapeutics ·Sani H. Kizilbash,Shiv K. Gupta,Kenneth Tou En Chang,(unknown),Karen E. Parrish,Brett L. Carlson,Katrina K. Bakken,Ann C. Mladek,Mark A. Schroeder,Paul A. Decker,Gaspar J. Kitange,Yuqiao Shen,Ying Feng,Andrew A. Protter,William F. Elmquist,Jann N. Sarkaria	60
12	The Selective ATR Inhibitor VX-970 Enhances the Therapeutic Effects of Radiation Therapy in Triple Negative Breast Cancer Patient-Derived Xenografts and is a Novel Strategy to Overcome Therapeutic Resistance 2017 ·International Journal of Radiation OncologyBiologyPhysics ·Robert W. Mutter,(unknown),Mohamed M. Kahila,Xiaolin Yu,Mark A. Schroeder,Brett L. Carlson,(unknown),(unknown),(unknown),Jann N. Sarkaria,Zhenkun Lou	2
13	Extracellular Hyaluronic Acid Influences the Efficacy of EGFR Tyrosine Kinase Inhibitors in a Biomaterial Model of Glioblastoma 2017 ·Advanced Healthcare Materials ·Sara Pedrón,(unknown),Mark A. Schroeder,Jann N. Sarkaria,Brendan A.C. Harley	44
14	Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System 2015 ·Molecular Cancer Therapeutics ·Karen E. Parrish,Ling Cen,J. C. Murray,David Calligaris,Sani H. Kizilbash,Rajendar K. Mittapalli,Brett L. Carlson,Mark A. Schroeder,Julieann Sludden,Alan V. Boddy,Nathalie Y.R. Agar,Nicola J. Curtin,William F. Elmquist,Jann N. Sarkaria	66
15	The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma 2015 ·Clinical Cancer Research ·Jenny L. Pokorny,David Calligaris,Shiv K. Gupta,(unknown),(unknown),Katrina K. Bakken,Brett L. Carlson,Mark A. Schroeder,Debra L. Evans,Zhenkun Lou,Paul A. Decker,Jeanette E. Eckel‐Passow,Vincenzo Pucci,Bennett Ma,Stuart D. Shumway,William F. Elmquist,Nathalie Y.R. Agar,Jann N. Sarkaria	71
16	Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts 2014 ·Clinical Cancer Research ·Shiv K. Gupta,Ann C. Mladek,Brett L. Carlson,Felix Boakye‐Agyeman,Katrina K. Bakken,Sani H. Kizilbash,Mark A. Schroeder,Joel M. Reid,Jann N. Sarkaria	57
17	Cyclophilin B Supports Myc and Mutant p53-Dependent Survival of Glioblastoma Multiforme Cells 2013 ·Cancer Research ·Jae Won Choi,Mark A. Schroeder,Jann N. Sarkaria,Richard J. Bram	32
18	Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts 2012 ·Clinical Cancer Research ·Gaspar J. Kitange,Ann C. Mladek,Brett L. Carlson,Mark A. Schroeder,Jenny L. Pokorny,Ling Cen,Paul A. Decker,Wenting Wu,Gwen Lomberk,Shiv K. Gupta,Raúl Urrutia,Jann N. Sarkaria	125
19	Retargeted Oncolytic Measles Strains Entering via the EGFRvIII Receptor Maintain Significant Antitumor Activity against Gliomas with Increased Tumor Specificity 2006 ·Cancer Research ·Cory Allen,Sompong Vongpunsawad,Takafumi Nakamura,C. David James,Mark A. Schroeder,Roberto Cattaneo,Caterina Giannini,James Krempski,Kah-Whye Peng,(unknown),Joon H. Uhm,Stephen J. Russell,Evanthia Galanis	84
20	EXPERIMENTAL EMPHYSEMA 1995 ·Chest Surgery Clinics of North America ·Claude Deschamps,G. A. Farkas,Kenneth C. Beck,Mark A. Schroeder,Robert E. Hyatt	1

About Mark A. Schroeder

Mark A. Schroeder is a scholar working on Hematology, Genetics and Oncology, having authored 213 papers that have together received 7.0k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (50 papers), Glioma Diagnosis and Treatment (36 papers) and Acute Myeloid Leukemia Research (34 papers). The work is most often cited by research in Genetics (1.8k citations), Hematology (1.4k citations) and Oncology (1.8k citations). Mark A. Schroeder has collaborated with scholars based in United States, Canada and Australia. Frequent co-authors include Jann N. Sarkaria, Brett L. Carlson, John F. DiPersio, Mark S. Wrighton, C. David James, Rolf D. Hubmayr, Nicholas E. Vlahakis, Evanthia Galanis, Caterina Giannini and Gaspar J. Kitange. Their work appears in journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and Genes & Development.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact